Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
https://www.labmanager.com/business-management/trends-in-lab-automation-27138
A response as useful as a chocolate fire guard...
thanks for trying...
Trumpton Town
FYI, I did get a response:
Thank you for your enquiry regarding Deepmatter.
Deepmatter publishes all its formal announcements for all shareholders through the RNS feed. These are subject to the Group's AIM regulatory obligations and in accordance with customer confidentiality obligations.
The Group is unable to comment on specific customers or products beyond these formal announcements.
Kind regards
But I did manage to get a response:)
You win some and you loose some, ha ha
OB
Evening
Well as I have said before if this goes below 1p, I will double my holding…
Jolly, come on fella please play nicely we are all just normal folk trying to invest in what we believe in, for me it’s all about early retirement… hopefully?
My aspirations are probably the same as yours?
Don’t get me wrong I am not afraid of an opposing opinion, but please be respectful to others…
OB
its all down to riddler posting here in the past, some reason jolly cant stay away maybe they were a couple at some point...lovers!
totally agree some people have lost a fair lump here, slime ball gloating at peeps effin poor
lets hope for some misfortune your end jolly ive my fingers crossed tight
laughing at your efforts, not (all your) misfortunes
where's that genius/guru, rids, lol?
Laughing at peoples misfortune... what an odious person you must be...
he he
tp <<1p
Bore off Jolly....
all pretty irrelevant...where's the fcf???
cashburn is what matters imv
#placement
1/12/21 even…oops!
The following highlights many of the reasons why am a buyer at this level:
Dmtr
Share price 1.175 p, market cap 11million (as of today 1/10/21)
52 week high 3.05p, low 1.15p (as of today 1/10/21)
Last results : Sept 2020
Revenues: maiden revenues £1mln
Cash raised £2.1mln July 2020 enough till 2023+
= £4mln in cash as of August 2020
Company aim :
Create a shared data cloud where the platform is designed to enable chemists to work together effectively; sharing the details of their experiments from anywhere and in real-time, so that work is not needlessly duplicated, time and money wasted, and ultimately so new discoveries may be made and solving an annual $30bln reproducibility crisis in drug and compound development.
Clients include:
Glaxo, Astrazenica , Waters,BASF, Cancer Research Uk, and in July 2020 Novartis and as of Oct 2020 they also gained 5 of the worlds largest pharmacy and agritech
Merck Jan 2021
Major shareholders (top 5) Sept 2020
1 IP group 29.5% and add 50mln of the 140mln new shares
2 Richard Griffiths 7%
3 Springer Nature 7%
4Prof Lee Cronin (scientific founder) 6.5% and added 1.2mln
5 Robert Quested 4.9%
Recent developments 2020
*Feb 2020 Chemify ( linked to Cronin lab) part of a grant funded project in:
"Developing a chemical ontology is the first step towards the digitization of chemistry, the UK pharmaceutical market is set to grow from $32B in 2016 to $43B by 2020, with around 5,000 UK companies in the area. In this proposal, we will interact with key companies (Deep Matter and GSK) "
*Astra/Glaxo form part of the Uk government hub with bases in Oxford, Glasgow and others cities.
* Astrazenica had signed an agreement in 2019 work with DMTR to " transform drug design using innovative digital technologies in combination with automation and AI. To get potential new medicines to patients faster"
*Cancer Research at Beatson Glasgow to divert energy to tracking C19 and signed a deal with DMTR on 14th April for:
the sharing of details of their experiments from anywhere and in real-time
A subsequent deployment in China is anticipated to take place later in 2020.
*June : signs collaboration with one of worlds leading companies in the chemicals sector called Waters.
*July working with £200bln valued Novartis
*Sept confirm record revenues and new customers
*Oct :announce they are working with 5 of largest pharmacy and agritech companies
*Dec 2020 multi year agreement with a world leading company Theines
part of the Thieme Group, an award-winning international medical and science publisher serving health professionals and students for more than 130 years, for the supply of technical data services and access to the Group's proprietary algorithms.
Jan 2021
*Signs deal with Merck